-
Catalyst Biosciences Stock Moves Higher On Additional FDA Fast Track Tag For MarzAA
28 Jun 2021 12:55 GMT
… bleeding in subjects with Factor VII deficiency.
Catalyst is currently … -label study. The trial is conducted in parallel … the ongoing Phase 3 trial evaluating MarzAA to treat … drug candidates.
FDA granted Fast Track Designation for MarzAA for the SQ treatment …
-
BRIEF-Catalyst Bio - Plans To Initiate Phase 1/2 Trial Of Marzaa In Factor Vii Deficiency, Glanzmann Thrombasthenia, And Hemlibra Patients In Q4
17 Jun 2020 20:27 GMT
… PHASE 1/2 TRIAL OF MARZAA IN FACTOR VII DEFICIENCY, GLANZMANN THROMBASTHENIA …
-
Catalyst Biosciences Presents Pre-clinical SQ Treatment of Bleeds Data from its Marzeptacog alfa (activated) (MarzAA) Program at the 14th Annual EAHAD Congress
03 Feb 2021 13:00 GMT
… activated coagulation Factor VII (FVIIa) for the treatment of episodic … /2 trial of MarzAA in Factor VII Deficiency, Glanzmann … Catalyst Biosciences, the Protease Medicines company
Catalyst is a … , that additional human trials will not replicate the …
-
Device protects human liver cells producing critical biomolecules for six months in mice
12 Oct 2021 13:26 GMT
… act as a sort of drug store to deliver key biomolecules … treat type 1 diabetes or factor VII or factor IX to treat … donors and recipients combined with drugs to suppress the patient…
-
Pfizer doses first patient in investigational haemophilia drug trial
25 Nov 2020 13:36 GMT
… marstacimab, an investigational drug being evaluated for the treatment of severe haemophilia … all participants involved in the trial.
The participants were also monitored … number of treatments on the market are designed to replace factor VII, including …
-
Catalyst Biosciences: After 2 Fundraisings, A Lengthy Wait For Pivotal Trial Data Is Next
14 Nov 2020 01:47 GMT
… and commercialise the drug, as well as … trial) as a treatment for Glanzmann Thrombasthenia, Acquired Hemophilia, Factor VII … form since 2008. Takeda Pharmaceutical'; (TAK) FEIBA … biotech) $37.3m. Pandemic pressures could delay the progress of trials …
-
FDA blocks much-anticipated BioMarin hemophilia gene therapy
19 Aug 2020 16:04 GMT
… HILLS, PA — Investors fled drug developer BioMarin in droves on … had been highly anticipated by doctors, patients and investors.
Called … 150 IV infusions of Factor VII per year to prevent … .
In midday trading, Biomarin Pharmaceutical Inc. shares plunged $40. …
-
Contaminated Blood Scandal: Inquiry plans to resume in September with doctors to be quizzed after coronavirus saw summer hearings cancelled
20 Jul 2020 20:36 GMT
… 20 July 2020
Sam Volpe
Factor VII blood products, Sir Brian Langstaff … will resume in September, with medical staff to give evidence over … were given by doctors in the course of medical care. The inquiry …
-
Hemophilia A Market Analysis, Epidemiology, Key Companies and Emerging Drugs
08 May 2020 01:56 GMT
… treatment with bypassing agents (e.g. recombinant activated factor VII … of each drug.
Report’s Drugs Uptake section helps … such as
Biomarin Pharmaceutical
Novo Nordisk
Sanofi
… Hemophilia A Treatment Algorithm, Current Treatment, and Medical Practices
9. …
-
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT(R) [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
06 Apr 2020 13:50 GMT
… .S. Food and Drug Administration (FDA) approved SEVENFACT® … indicated for treatment of congenital factor VII deficiency.
Important … and seek appropriate medical intervention.
Adverse Reactions … leading European bio-pharmaceutical companies providing mainly …
About
© 1995-2021